Chair, Human Oncology and Pathogenesis Program
Memorial Sloan Kettering Cancer Center
New York, New York
For discovering tyrosine kinase inhibitor resistance mechanisms, specifically those involving imatinib in patients with chronic myeloid leukemia and for his contributions to the development of dasatinib for patients with imatinib-resistant CML and enzalutamide for docetaxel-resistant metastatic prostate cancer.
Dr. Sawyers delivered his award lecture titled, “Linage Plasticity in Cancer,” Monday, April 1, 2019, during the AACR Annual Meeting 2019 at the Georgia World Congress Center.